Esperion Therapeutics Files 8-K on Financials

TL;DR

Esperion Therapeutics dropped an 8-K detailing their latest financial results.

AI Summary

Esperion Therapeutics, Inc. filed an 8-K on January 16, 2025, reporting on its results of operations and financial condition as of January 15, 2025. The filing details financial statements and exhibits related to the company's performance.

Why It Matters

This 8-K filing provides investors with crucial updates on Esperion Therapeutics' financial health and operational results, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing with no immediate new material events disclosed.

Key Players & Entities

• Esperion Therapeutics, Inc. (company) — Registrant
• January 15, 2025 (date) — Date of Earliest Event Reported
• January 16, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Ann Arbor, MI (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC
• $55 million — nses are expected to be in the range of $55 million to $65 million; (ii) selling, general a
• $65 million — ed to be in the range of $55 million to $65 million; (ii) selling, general and administrati
• $160 — nses are expected to be in the range of $160 to $170 million; and (iii) operating ex
• $170 million — expected to be in the range of $160 to $170 million; and (iii) operating expenses are expec
• $215 million — nses are expected to be in the range of $215 million to $235 million. Selected slides from t
• $235 million — d to be in the range of $215 million to $235 million. Selected slides from the Company's pre

Filing Documents

• espr-20250115.htm (8-K) — 28KB
• jpmslides.htm (EX-99.1) — 2KB
• espr2025jpmpresentation1.jpg (GRAPHIC) — 166KB
• espr2025jpmpresentation2.jpg (GRAPHIC) — 241KB
• espr2025jpmpresentation3.jpg (GRAPHIC) — 142KB
• 0001628280-25-001672.txt ( ) — 911KB
• espr-20250115.xsd (EX-101.SCH) — 2KB
• espr-20250115_lab.xml (EX-101.LAB) — 22KB
• espr-20250115_pre.xml (EX-101.PRE) — 13KB
• espr-20250115_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 15, 2025, Esperion Therapeutics, Inc. (the "Company") announced in its management presentation at the 43 nd Annual J.P. Morgan Healthcare Conference the following financial guidance for the fiscal year ending December 31, 2025, which guidance is based on management's current expectations for the business: (i) research & development expenses are expected to be in the range of $55 million to $65 million; (ii) selling, general and administrative expenses are expected to be in the range of $160 to $170 million; and (iii) operating expenses are expected to be in the range of $215 million to $235 million. Selected slides from the Company's presentation are attached as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about the Company's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as "may," "will," "could," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and similar expressions, or the negative of these terms. These forward-looking statements include statements about the Company's expected full year expenses and financial performance. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward- looking statements are qualified in their entirety by reference to the factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and in the Company's other reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Slides from Presentation of the Company, dated January 15, 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 16, 2025 Esperion Therapeutics, Inc. By: /s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR